Clinical Trials Logo

Clinical Trial Summary

The study is designed to evaluate the safety, reactogenicity, and immunogenicity of three groups of healthy volunteers who receive either intranasal single dose (vaccine on Day 0 and placebo on Day 28) or two-dose (vaccine on Day 0 and 28) of BBV154 vaccine or Placebo (on Day 0 and day 28). A total of 175 subjects will be enrolled in 2:2:1 ratio and will be conducted in a double-blinded manner. To assess the safety of the vaccine, each participant will record symptoms in a diary card for 7 days after each dose. Safety and laboratory tests and physical exams will also be performed. Blood samples and saliva samples be collected to assess the immune response from the vaccine. An interim report based on the safety and immunogenicity of the vaccine (BBV154) will be notified to the Central Drugs Standard Control Organization (CDSCO), India, for further progressing the clinical development of the vaccine. This unblinded interim report will contain a detailed analysis of the data based on the primary and secondary objectives of all visits through Day 42 (Immunogenicity & Safety).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04751682
Study type Interventional
Source Bharat Biotech International Limited
Contact
Status Completed
Phase Phase 1
Start date March 1, 2021
Completion date November 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546776 - COVID-19 Persistence in Stool
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Recruiting NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Completed NCT04516928 - Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Completed NCT04733625 - The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection N/A
Completed NCT04550390 - Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Active, not recruiting NCT04517136 - Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Recruiting NCT04476680 - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion N/A
Completed NCT04839913 - Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
Completed NCT04514874 - Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
Terminated NCT04606563 - Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Phase 3
Completed NCT05234359 - The CHILD Cohort COVID-19 Add-On Study